Doxil

Product manufactured by Janssen Products, Lp

Application Nr Approved Date Route Status External Links
NDA050718 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Doxil Is An Anthracycline Topoisomerase Inhibitor Indicated For: Ovarian Cancer: After Failure Of Platinum-Based Chemotherapy ( 1.1 ) Aids-Related Kaposi's Sarcoma: After Failure Of Prior Systemic Chemotherapy Or Intolerance To Such Therapy ( 1.2 ). Multiple Myeloma: In Combination With Bortezomib In Patients Who Have Not Previously Received Bortezomib And Have Received At Least One Prior Therapy ( 1.3 ). 1.1 Ovarian Cancer Doxil Is Indicated For The Treatment Of Patients With Ovarian Cancer Whose Disease Has Progressed Or Recurred After Platinum-Based Chemotherapy. 1.2 Aids-Related Kaposi's Sarcoma Doxil Is Indicated For The Treatment Of Aids-Related Kaposi's Sarcoma In Patients After Failure Of Prior Systemic Chemotherapy Or Intolerance To Such Therapy. 1.3 Multiple Myeloma Doxil, In Combination With Bortezomib, Is Indicated For The Treatment Of Patients With Multiple Myeloma Who Have Not Previously Received Bortezomib And Have Received At Least One Prior Therapy.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Doxorubicin Hydrochloride DOXORUBICIN HYDROCHLORIDE ZINC3918087

Comments